The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J05 | Antivirals for systemic use | |
| 3 | J05A | Direct acting antivirals | |
| 4 | J05AG | Non-nucleoside reverse transcriptase inhibitors | |
| 5 | J05AG05 | Rilpivirine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 25 mg |
| Active Ingredient | Description | |
|---|---|---|
| Rilpivirine |
Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EDURANT Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| REKAMBYS Prolonged-release suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
